Carbidopa NDC 43386-980

NDC codes

FDA NDC Directory

Product NDC (as listed)43386-980Labeler and product segments. Claims need a package NDC.

Product NDC at billing width43386-0980Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
43386-980-01	43386098001	100 TABLET in 1 BOTTLE (43386-980-01)Marketed from Oct 20, 2017

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Carbidopa
Generic name (nonproprietary): carbidopa
Active ingredients: Carbidopa — 25 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Lupin Pharmaceuticals,Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 204763
Marketing start: Oct 20, 2017
Listing expires: Dec 31, 2026
Identifiers: Product ID 43386-980_13400de7-964e-4752-836d-6d87e466b84bSPL ID 13400de7-964e-4752-836d-6d87e466b84bSPL set ID e95b1ab8-0fd9-4399-897a-5ae73b36af45RxCUI 260260UNII MNX7R8C5VOUPC 0343386980017, 0343386980031, 0343386980109

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N443386098001 followed by a unit qualifier and the quantity

Package 43386-0980-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jan 30, 2024.

Indications (excerpt from the label)

INDICATIONS AND USAGE Carbidopa tablets are indicated for use with carbidopa-levodopa or with levodopa in the treatment of the symptoms of idiopathic Parkinson's disease (paralysis agitans), postencephalitic parkinsonism, and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication and/or manganese intoxication. Carbidopa is for use with carbidopa-levodopa in patients for whom the dosage of carbidopa-levodopa provides less than adequate daily dosage (usually 70 mg daily) of carbidopa. Carbidopa is for use with levodopa in the occasional patient whose dosage requirement of carbidopa and levodopa necessitates separate titration of each medication. …

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 204763

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 204763
Product	Strength	Form · route	Labeler	Product NDC
Carbidopa	Carbidopa 25 mg/1	TabletOral	Novel Laboratories, Inc.	40032-980